Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Lymphoma Clinical Trial

Official title:

An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02282358
• Other study ID #: 14-106
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: October 2014
• Est. completion date: May 26, 2023

Study information

• Verified date: May 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn if the study drug mocetinostat can slow the progression of cancer in people who have a mutation in CREBBP or EP300 in the genetic makeup of their cancer. The potential side effects of mocetinostat will also be studied.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: May 26, 2023
• Est. primary completion date: May 26, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient has provided a signed study Informed Consent Form prior to performance of any study related procedurePatient is = 18 years of age

• Patient has histologically confirmed diagnosis of diffuse large B cell lymphoma or follicular lymphoma harboring mutations in CREBBP or EP300 with relapsed or refractory disease

• Patients with diffuse large B cell lymphoma must have received at least two prior therapies and have received, declined or be ineligible for autologous or allogeneic stem cell transplant.

• Patients with follicular lymphoma must have received at least two prior therapies.

• Patients with either diffuse large B cell lymphoma or follicular lymphoma will be allowed to enroll after receiving only 1 prior therapy if they are felt to not be a candidate for further systemic chemotherapy.

• Patient has at least one measurable lesion (= 2 cm) according to Cheson criteria [45]. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status = 1 - Patient has adequate bone marrow and organ function by:

Absolute neutrophil count (ANC) = 1.0 x 10^9/L

• Platelets = 75 x 10^9/L (no platelet transfusion within past 14 days)

• Hemoglobin (Hgb) = 9.0 g/dL (no RBC transfusion within past 14 days)

• International Normalized Ratio (INR) = 1.5

• Serum Creatinine = 1.5 x upper limit of normal (ULN)

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN, or = 5.0 x ULN for patients with documented hepatic involvement

• Serum bilirubin = 1.5 x ULN or = 3.0 x ULN for patients with Gilbert Syndrome or documented hepatic involvement.

• Patients must have fully recovered from major surgery and from the acute toxic effects of prior chemotherapy and radiotherapy (residual grade 1 toxicity, e.g. grade 1 peripheral neuropathy, and residual alopecia are allowed)

Exclusion Criteria:

• Patient has received previous treatment with HDAC inhibitors

• Patient has evidence of graft versus host disease (GVHD)

• Patient has active or history of central nervous system (CNS) disease

• Patient has impaired cardiac function including any of the following:

• Presence or history of pericardial effusion (definitions are provided in and/or pericarditis.

• Acute myocardial infarction, symptomatic angina pectoris = 6 months prior to starting study drug

• Presence of congestive heart failure = NYHA class 3

• QTc > 480 ms on a screening ECG

• Screening LVEF < 45% by echocardiography or MUGA

• Uncontrolled cardiac arrhythmia including uncontrolled atrial fibrillation/atrial flutter/sinus tachycardia, complete left bundle branch block, congenital long QT syndrome

• Presence of permanent cardiac pacemaker

• Other clinically significant heart disease

• Subject is taking warfarin at start of treatment or within 6 months prior to start of study treatment.

• Patient has a concurrent malignancy or has a malignancy within 3 years of study enrollment (with the exception of adequately treated basal or squamous cell carcinoma or nonmelanomatous skin cancer)

• Patient is concurrently using other approved or investigational antineoplastic agent

• Patient has received chemotherapy, targeted anticancer therapy, pelvic and/or para-aortic radiotherapy or has had major surgery = 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy

• Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of mocetinostat (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

• Patient is currently receiving increasing or chronic treatment (> 10 days) with corticosteroids or another immunosuppressive agent. The following uses of corticosteroids are permitted: single dose, topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops or local injections (e.g., intra-articular).

• Patient has a history of non-compliance to medical regimen or inability to grant consent.

• Concomitant medications causing prolonged QT which cannot be discontinued or changed to a different medication prior to initiating study

• Patient is currently being treated with drugs known to be moderate or strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Patients must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the start of treatment.

Note: the oral anti-diabetic drugs troglitazone and pioglitazone are CYP3A inducers.

• Patient has a known history of HIV (testing not mandatory), active Hepatitis B or C infection.

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive serum hCG laboratory test (> 5 mIU/mL)

• Women of child bearing potential and men with reproductive potential, if they are unwilling to use adequate contraception while on study therapy and for 3 months thereafter

Related Conditions & MeSH terms

• Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
• Lymphoma
• Lymphoma, B-Cell
• Lymphoma, Follicular
• Lymphoma, Large B-Cell, Diffuse
• Relapsed and Refractory

Intervention

Drug:
• Mocetinostat

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	MethylGene Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy as Defined by Overall Response	as defined by overall response rate of Mocetinostat at one year in patients with relapsed/refractory DLBCL and FL who have inactivating mutations of acetyltransferase genes. Response will be measured according to the 2007 revised Cheson criteria for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=50% decrease in sum of the product of the diameters (SPD) of up to 6 dominant lesions identified at baseline; Overall Response (OR) = CR + PR.	1 year
Secondary	Event Free Survival	defined as time from the date of treatment start to the date of the first documented progressive disease (PD) or death due to any cause) rate using mocetinostat in this selected population will be estimated by the Kaplan-Meier method. Relapsed disease/progressive disease is defined as at least 50% increase of target measurable nodal lesions	up to 17.8 months
Secondary	Median Progression Free Survival/PFS	is defined as the time from the date of first occurrence of CR or PR whichever is recorded first to the date of the first objectively documented progressive disease (PD) or death due to any cause. The duration of response will be assessed based on the sub-cohort of patients who showed responses also using Kaplan-Meier.	up to 17.8 months
Secondary	Number of Participants Evaluated for Toxicity According to the (NCI CTCAE) Version 4.0.	will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.0.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center